Third, our previous study demonstrated that TIGIT blockade, but not PD-L1 blockade, elicited potent antitumor immunity in a mouse model of naturally occurring HBV-related HCC, suggesting that TIGIT may be a novel target for HCC immunotherapy (5). This evidence concerns the gene CD274 and hepatocellular carcinoma.